|
Getting your Trinity Audio player ready...
|
In a market increasingly driven by breakthrough science and resource scarcity, a handful of sub-$2 stocks are making headlines with bold strategies, compelling partnerships, and game-changing data. From immunotherapy innovations to neuromodulation tech, metallic-rich exploration zones and wireless signal innovation, these companies are pushing the envelope—and attracting serious investor attention in the process.
Power Metallic Inc. (TSX.V: PNPN | OTCQB: PNPNF): The Green Metals Gem in a Battery Metals Supercycle
With gold, silver, and copper hitting record highs, Power Nickel has become one of the most exciting junior mining stocks under $2. The company is riding the wave of investor interest in nickel and copper exploration, reporting its deepest and most promising nickel-copper intercepts from the Lion Zone at its flagship NISK Project in Quebec. The recently confirmed Tiger Zone assays add even more upside.
Backed by C$50M in capital and a drilling expansion in full swing, Power Nickel is emerging as a key player in the global shift to battery metals and green energy. As investor searches surge for terms like “EV battery metals stock 2025” and “nickel stock to watch”, PNPN stands out as a deeply undervalued name in one of the decade’s hottest macro environments.
Tivic Health Systems, Inc. (NASDAQ: TIVC): Reverse Split, $25M Line, and Wearable FDA Biotech Push
Tivic Health is evolving into a wearable biotech hybrid, recently completing a 1-for-17 reverse stock split to regain Nasdaq compliance—boosting visibility among “reverse split biotech” searches. Backed by a $25M equity line, Tivic is advancing Entolimod™, a late-stage radiation therapy, and expanding its ncVNS neuromodulation platform with the Feinstein Institute. With 87 patents and a push into FDA-driven wearable tech, Tivic is targeting fast-emerging categories like “non-invasive biotech device stock.”
Aptevo Therapeutics (NASDAQ: APVO): 90% Remission in AML, No CRS
Aptevo’s ADAPTIR® platform is gaining traction after 9 of 10 AML patients achieved remission in its RAINIER trial using triplet therapy—far exceeding standard outcomes. Notably, no Cytokine Release Syndrome (CRS) has been reported, making it a standout in the cancer immunotherapy space. With phrases like “90% remission biotech” and “CRS-free AML therapy” trending, APVO is a top contender for biotech watchlists.
OSR Holdings, Inc. (NASDAQ: OSRH): $80M Funding Boost for GBM Vaccine Development
OSR Holdings secured an $80M stock purchase agreement to accelerate its glioblastoma (GBM) vaccine, VXM01, developed by its Swiss subsidiary, Vaximm. With a global reach across the U.S., Europe, and Asia, OSR is gaining traction in the niche GBM immunotherapy space—drawing investor searches like “glioblastoma vaccine stock” and “Korean biotech under $2.” OSRH could be a sleeper hit in next-gen brain cancer treatment.
Peraso Inc. (NASDAQ: PRSO): 50% Capacity Boost Powers Urban 60 GHz Wireless 5G Rollout
Peraso upgraded its PERSPECTUS module, increasing supported devices per access point from 32 to 48—a 50% capacity jump for its 60 GHz fixed wireless access (FWA) tech. This benefits WISPs in dense cities with faster speeds (up to 2 Gbps), lower power use, and fewer hardware needs. Active deployments in Los Angeles and potential access to $42B in BEAD broadband funding position PRSO for urban and underserved market growth.
Value Now, Catalysts and Growth
While many investors chase headlines at premium valuations, these four companies—each trading under $2—offer a compelling blend of innovation, execution, and upcoming catalysts. Whether it’s precious, battery, energy, base metals exploration, wearable FDA tech, cancer immunotherapy, global vaccine development or wireless signal innovation, PNPN, TIVC, APVO, OSRH and PRSO are positioned for breakout potential. Stay tuned on these tickers.